Navigation Links
A hot road to new drugs
Date:2/24/2010

The search for new therapeutic agents is time-consuming and expensive. Pharmaceutical companies may have to screen thousands of compounds for the ability to bind a target molecule before they hit upon a promising drug candidate. A group of Biophysicists at LMU Munich led by Professor Dieter Braun, a member of the Cluster of Excellence "Nanosystems Initiative Munich" (NIM), and a partner in NanoTemper (an LMU spin-off), have now developed a unique technology called "microscale thermophoresis" that allows to measure intereactions under close-to-native conditions, thus improving the decision making process in drug development. The technique takes advantage of the Soret effect the tendency of molecules to drift along temperature gradients, usually from warm to cold. If a compound encounters and binds to another molecule, its thermophoretic parameters change, and its trajectory may even be reversed. This phenomenon can be exploited to determine whether a molecule that is known to play a causative role in a given disease binds to a test substance. In the test, which can be carried out directly on blood samples, the thermodiffusion of a labelled biomolecule of interest is measured in the presence and absence of a candidate binding agent. If the two bind together to form a complex, the resulting change in their thermophoretic behaviour can be detected. "Detection of binding activity is the first step on the road to a new drug", says Braun. "The new method also has potential applications in medical diagnostics, and in food and environmental monitoring."

The procedures conventionally used to identify candidate drugs are normally carried out in artificial buffer solutions, and the results often have little relationship to a compound's binding affinity for its target in the blood. The new thermophoretic technique, on the other hand, allows one to perform the binding test directly in a blood sample and therefore gives more reliable results. The substance to be tested is mixed with a blood sample containing a target that is known to be associated with a disease state and has been labelled with a fluorescent tag. A tiny drop of the mixture is taken up into a thin glass capillary tube, and a focused beam of IR-laser light is used to heat a small volume of the solution in the middle of the tube. This gives rise to a temperature gradient that falls off towards the outside. The response of the labelled molecule to the variation in temperature can then be followed using fluorescence methods.

Upon heating of the sample, it immediately becomes apparent whether or not the fluorescent target-molecules in the sample behave differently in the presence of the drug test compound than they do in its absence. Any difference in thermophoresis between the two samples indicates that the test substance binds to the labelled target, and provides the first hint that it may have therapeutic potential. "Our method will not only be a boon to drug discovery", says Braun. "It can also be used in medical diagnostics, food testing and environmental monitoring. One could, for instance, employ it to diagnose autoimmune diseases and infections, or as the basis for a rapid test for the presence of antibiotics in milk or toxic substances in water." (NIM/suwe)


'/>"/>

Contact: Prof. Dieter Braun
49-892-180-2317
Ludwig-Maximilians-Universitt Mnchen
Source:Eurekalert

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
3. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
4. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
5. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
6. So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market
7. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
8. Amazing Treatment Relieves Serious Back Pain Without Dangerous Drugs, Injections or Surgery!
9. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
10. Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs
11. Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Whitehouse, NJ (PRWEB) , ... January 18, 2017 ... ... access to more and more E&L expertise. Within Albany Molecular Research, Inc. (AMRI), ... doubled in the past year and is planned for further growth in 2017. ...
(Date:1/18/2017)... ... 2017 , ... Researchers from a new study are stating that if levels of ... cancer treatment, this indicates there is still remaining prostate cancer cells that are more likely ... test has always been an indicator of whether a man’s prostate cancer is growing ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... the publishing of the latest paper by its Science Editor, Dr. Elisabeth Bik, ... Tijdschrift voor Medische Microbiologie). Dr. Bik joined uBiome in October 2016 from her ...
(Date:1/18/2017)...  HUYA Bioscience International, (HUYA), the leader in accelerating ... pharmaceutical innovations, announced today a strategic collaboration agreement with ... (referred to as CAS Innovation). The collaboration will focus ... scientists at CAS to meet the medical needs of ... first company to have recognized China,s ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec 15, 2016 ... Research and Markets has announced the addition ... offering. The report forecasts the global military biometrics market ... The report has been prepared based on an in-depth market ... and its growth prospects over the coming years. The report also includes ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
(Date:12/8/2016)... 2016  Singulex, Inc., the leader in Next Generation ... a license and supply agreement with Thermo Fisher Scientific, ... Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), a ... used to diagnose systemic bacterial infection and sepsis and ... aid in assessing the risk of critically ill patients ...
Breaking Biology News(10 mins):